Investment Recommendations for Zoetis and Energy Transfer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: CNBC
- Zoetis Investment Warning: Zoetis's performance has raised concerns, with analysts expressing a preference for Elanco for the first time, indicating potential challenges for Zoetis in the animal health sector that could impact market confidence and stock performance.
- Energy Transfer Investment Opportunity: Energy Transfer is viewed as a highly attractive investment option, with analysts noting its undervalued stock price and good dividend yield, likely appealing to investors seeking stable income.
- Market Sentiment Shift: The contrasting negative outlook for Zoetis and positive sentiment for Energy Transfer reflects differing expectations in the market, which may lead investors to reassess their portfolios.
- Long-term Investment Strategy: Jim Cramer recommends focusing on Energy Transfer's investment potential, emphasizing its undervalued status and stable dividend yield, which could provide investors with long-term wealth growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 81.290
Low
130.00
Averages
154.20
High
200.00
Current: 81.290
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Facing Class Action Lawsuits
- Calix, Inc. Lawsuit: During the period from January 28 to April 21, 2026, Calix is accused of concealing that its first-quarter margins benefited from advanced purchasing of memory components, leading to a misunderstanding of the company's prospects, which could negatively impact its stock performance.
- AeroVironment, Inc. Allegations: From June 25, 2025, to March 10, 2026, AeroVironment is accused of underestimating imminent competition for the SCAR program, resulting in overstated business prospects that could undermine investor confidence.
- Zoetis Inc. Issues: Between January 14 and May 6, 2025, Zoetis allegedly failed to disclose that veterinarian prescription growth was sharply weakening due to FDA safety warnings, which could lead to a decline in market share and affect future earnings.
- Lucid Group, Inc. Lawsuit: From February 25 to April 13, 2026, Lucid faced significant delivery disruptions due to supplier quality issues, which materially impacted its business and financial results, potentially causing losses for investors.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Market Share Decline: The lawsuit alleges that Zoetis' veterinarian prescription growth and market share for flagship products have significantly weakened due to FDA safety warnings, resulting in investor losses when the true situation became known.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements during the class period, claiming strong market share and sales growth, while in reality, the adoption of its key products was sharply declining, resulting in investor losses.
- Market Share Decline: Zoetis' Simparica Trio has lost significant market share to a lower-priced competing product with broader indications, indicating a slowdown in the overall market, which could impact future revenues.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and expertise, prompting investors to carefully select their legal counsel.
See More
Zoetis Faces Class Action Lawsuit Allegations
- Lawsuit Background: Zoetis Inc. is facing a class action lawsuit from the City of Ann Arbor Retiree Health Care Benefit Plan, alleging violations of the Securities Exchange Act of 1934 for securities transactions between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for investors to apply as lead plaintiffs.
- Market Performance Decline: The lawsuit claims that Zoetis' flagship products, including Librela and Simparica Trio, have experienced significant market share losses, particularly after FDA safety warnings led to a sharp decline in veterinarian prescriptions for Librela, causing the stock price to drop nearly 14% in November 2025.
- Financial Results Disclosure: On February 12, 2026, Zoetis reported its fourth quarter and full year 2025 financial results, revealing weakening demand trends and increasing competitive pressures in its animal health portfolio, which contributed to further stock price declines.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Zoetis securities during the class period can seek appointment as lead plaintiff, representing the interests of other investors, highlighting the lawsuit's potential impact on stakeholders.
See More
Zoetis Investors Advised of Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Zoetis investors of a class action lawsuit for those who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Declining Financial Performance: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7 per share, indicating a more challenging operating environment than previously anticipated.
- Severe Market Reaction: Following the earnings report on May 7, 2026, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, reflecting investor concerns over the company's future performance and a reassessment of its profitability.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy to discuss options for recovering losses, demonstrating the firm's commitment to supporting investor rights.
See More
Multiple Companies Facing Class Action Lawsuits
- Calix, Inc. Lawsuit: During the period from January 28 to April 21, 2026, Calix is accused of concealing that its first-quarter margins benefited from advanced purchasing of memory components, leading to a misunderstanding of the company's prospects, which could negatively impact its stock performance.
- AeroVironment, Inc. Allegations: From June 25, 2025, to March 10, 2026, AeroVironment is accused of underestimating imminent competition for the SCAR program, resulting in overstated business prospects that could undermine investor confidence.
- Zoetis Inc. Issues: Between January 14 and May 6, 2025, Zoetis allegedly failed to disclose that veterinarian prescription growth was sharply weakening due to FDA safety warnings, which could lead to a decline in market share and affect future earnings.
- Lucid Group, Inc. Lawsuit: From February 25 to April 13, 2026, Lucid faced significant delivery disruptions due to supplier quality issues, which materially impacted its business and financial results, potentially causing losses for investors.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Market Share Decline: The lawsuit alleges that Zoetis' veterinarian prescription growth and market share for flagship products have significantly weakened due to FDA safety warnings, resulting in investor losses when the true situation became known.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Zoetis made false or misleading statements during the class period, claiming strong market share and sales growth, while in reality, the adoption of its key products was sharply declining, resulting in investor losses.
- Market Share Decline: Zoetis' Simparica Trio has lost significant market share to a lower-priced competing product with broader indications, indicating a slowdown in the overall market, which could impact future revenues.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and expertise, prompting investors to carefully select their legal counsel.
See More
Zoetis Faces Class Action Lawsuit Allegations
- Lawsuit Background: Zoetis Inc. is facing a class action lawsuit from the City of Ann Arbor Retiree Health Care Benefit Plan, alleging violations of the Securities Exchange Act of 1934 for securities transactions between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for investors to apply as lead plaintiffs.
- Market Performance Decline: The lawsuit claims that Zoetis' flagship products, including Librela and Simparica Trio, have experienced significant market share losses, particularly after FDA safety warnings led to a sharp decline in veterinarian prescriptions for Librela, causing the stock price to drop nearly 14% in November 2025.
- Financial Results Disclosure: On February 12, 2026, Zoetis reported its fourth quarter and full year 2025 financial results, revealing weakening demand trends and increasing competitive pressures in its animal health portfolio, which contributed to further stock price declines.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Zoetis securities during the class period can seek appointment as lead plaintiff, representing the interests of other investors, highlighting the lawsuit's potential impact on stakeholders.
See More
Zoetis Investors Advised of Class Action Lawsuit
- Class Action Notification: The Portnoy Law Firm advises Zoetis investors of a class action lawsuit for those who purchased securities between January 14, 2025, and May 6, 2026, with a deadline of July 27, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Declining Financial Performance: Zoetis reported a net income of $601 million for Q1 2026, flat year-over-year, while cutting its full-year profit guidance to between $6.85 and $7 per share, indicating a more challenging operating environment than previously anticipated.
- Severe Market Reaction: Following the earnings report on May 7, 2026, Zoetis's stock price plummeted by $23.91, or 21.5%, closing at $87.31 per share, reflecting investor concerns over the company's future performance and a reassessment of its profitability.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy to discuss options for recovering losses, demonstrating the firm's commitment to supporting investor rights.
See More
